http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
UroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual Meeting
-
UroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate Developments
-
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
-
Phathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business Updates
-
UroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022
-
UroGen Pharma (URGN) Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
-
UroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
-
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
-
Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer
-
UroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate Developments
-
UroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow Breakeven
-
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
UroGen Pharma to Report Fourth Quarter and Full-Year 2021 Financial Results on Thursday, March 10, 2022
-
UroGen Pharma (URGN) Submits IND Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
-
UroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder Cancer
-
UroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare Conference
-
UroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by Patients
-
UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
-
UroGen Pharma to Present at Upcoming Conferences
-
First Patient Dosed in UroGen Pharma’s Home Instillation Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
-
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
-
UroGen Pharma Announces Upcoming 2021 Conferences
-
UroGen Pharma (URGN) Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
-
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
-
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
-
UroGen Pharma (URGN) Announces Journal of Urology Publishes Results of Phase 2b Study of UGN-102 in Patients with LG IR-NMIBC
-
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
-
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
-
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
-
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate Developments
-
Allogene Therapeutics (ALLO) Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
-
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
-
Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
-
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel
-
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021
-
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021
-
UroGen Pharma to Present at Ladenburg Thalmann Healthcare Conference
-
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
UroGen Pharma Announces June 2021 Conference Schedule
-
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate Developments
-
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021
-
UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Developments
-
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW Investments
-
UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology Pipeline
-
UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021
-
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
UroGen Pharma Announces March 2021 Conference Schedule
